Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6011709 | 0.90 | CYP3A4 (0.43) | PANK3LMNATSHRMAPK1RECQL | |
| SCHEMBL6011681 | 0.90 | SMN1; SMN2 (0.43) | LMNASMN1; SMN2MAPK1NPSR1HTT | |
| SCHEMBL7123726 | 0.89 | TP53 (0.42) | LMNATSHRSMN1; SMN2MAPK1RECQL | |
| SCHEMBL7127512 | 0.89 | TP53 (0.39) | PANK3LMNATSHRSMN1; SMN2MAPK1 | |
| SCHEMBL6011475 | 0.88 | LMNA (0.44) | PANK3LMNATSHRSMN1; SMN2MAPK1 | |
| SCHEMBL6011378 | 0.88 | SMN1; SMN2 (0.42) | PANK3LMNATSHRSMN1; SMN2MAPK1 | |
| SCHEMBL6011624 | 0.87 | CACNA1G (0.42) | SMN1; SMN2 | |
| SCHEMBL6011760 | 0.86 | KMT2A (0.42) | PANK3LMNASMN1; SMN2 | |
| SCHEMBL6011783 | 0.86 | HTT (0.44) | SMN1; SMN2NPSR1HTTTP53 | |
| SCHEMBL6011554 | 0.85 | MAPT (0.43) | PANK3LMNATSHRSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AZI2, QDPR, ADRA2A | HRH3 1453/4885PANK3 4729/4885LMNA 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.